© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

The company had planned to launch the generic version of Actos on August 17th, after a 2010 settlement with the Japanese drugmaker, Takeda Pharmaceuticals. Watson believes that the FDA improperly ...

David O. Watson, General Counsel of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), recently sold shares of the company amounting to $101,103. The transaction, which occurred on January 22, 2025, ...

David O. Watson, the General Counsel of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), recently sold a portion of his holdings in the company. According to a regulatory filing, Watson sold 695 shares of ...

Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Sildenafil Tablets, 20mg. Sildenafil is the ...

UK-based pharmaceutical company Icanthera said its cash reserves soared over the last year as it has struck a major deal and is focusing on developing new products. The company that manufactures ...

Morgan Stanley Raises Price Target On Watson Pharmaceuticals To $78 Morgan Stanley Raises PT On Watson Pharmaceuticals To $78 Morgan Stanley Raises Price Target On Watson Pharmaceuticals To $78 ...